London: Clinical Trial of 'omacetaxine' (ChemGenex Pharmaceuticals) for CML with the T3151 gene mutation
ChemGenex statement.
ChemGenex statement.
You are here
London: Phase ll Cinical trial of 'omacetaxine' (OM) for CML patients who have not responded to at least 2 TKI 's
A trial of omacetaxine for chronic myeloid leukaemia in people who cannot take tyrosine kinase inhibitors (TKIs) or whose leukaemia has not responded to TKIs
This trial is looking at a drug called omacetaxine (OM) for chronic myeloid leukaemia in people who have not responded to treatment with tyrosine kinase inhibitors.
A trial of omacetaxine for chronic myeloid leukaemia in people who cannot take tyrosine kinase inhibitors (TKIs) or whose leukaemia has not responded to TKIs
This trial is looking at a drug called omacetaxine (OM) for chronic myeloid leukaemia in people who have not responded to treatment with tyrosine kinase inhibitors.
DH publishes guidance on NHS patients who wish to pay for additional private care
Guidance on NHS patients who wish to pay for additional private care:
Executive summary
The key points which NHS organisations should take from this guidance are:
• NHS organisations should not withdraw NHS care simply because a patient chooses to buy additional private care.
Guidance on NHS patients who wish to pay for additional private care:
Executive summary
The key points which NHS organisations should take from this guidance are:
• NHS organisations should not withdraw NHS care simply because a patient chooses to buy additional private care.
Ros Shirran tells Yours Magazine how she was diagnosed with CML on her 51st birthday, but thanks to her son's persist... [more]
<h2>View the full article article as a <a href="http://www.cmlsupport.org.uk/files/Yours_Magazine59_Ros_Shirran_p38.jpg"... or download it as a <a href="http://www.cmlsupport.org.uk/files/YOUR059-38_I_beat_it.pdf">PDF</a> file.</h2>
![http://www.cmlsupport.org.uk/files/Yours_Magazine59_Ros_Shirran_p38.jpg"...](http://www.cmlsupport.org.uk/files/Yours_Magazine59_Ros_Shirran_p38.jpg">picture</a>){kind=link}
RARER CANCERS FORUM PROJECT: PATHWAYS TO DIAGNOSIS- Briefing notes and Data Collection Form
Dear RCF supporter,
We are hoping that volunteers with rarer cancers will be able to help us collect information about the process of diagnosis at GP level for people with rarer cancers. The aim of the project is to improve the diagnosis of rarer cancers and so help improve outcomes. Patients will need to ask their GP practice for access to their medical records and then use the attached data collection form to extract the information. The findings will be anonymised and written up in a report for the Department of Health. You will find more information about the project in the attached briefing notes.
Dear RCF supporter,
We are hoping that volunteers with rarer cancers will be able to help us collect information about the process of diagnosis at GP level for people with rarer cancers. The aim of the project is to improve the diagnosis of rarer cancers and so help improve outcomes. Patients will need to ask their GP practice for access to their medical records and then use the attached data collection form to extract the information. The findings will be anonymised and written up in a report for the Department of Health. You will find more information about the project in the attached briefing notes.
UK cancer specialists “not telling patients about new drugs” 26 August 2008
UK cancer specialists “not telling patients about new drugs”
26 August 2008
A quarter of doctors specialising in the cancer myeloma have admitted not telling their patients about expensive new drugs which have yet to be appraised by the National Institute for Health and Clinical Excellence, and nearly all of them said this was because they feared that doing so might “distress, upset or confuse” the patients.
UK cancer specialists “not telling patients about new drugs”
26 August 2008
A quarter of doctors specialising in the cancer myeloma have admitted not telling their patients about expensive new drugs which have yet to be appraised by the National Institute for Health and Clinical Excellence, and nearly all of them said this was because they feared that doing so might “distress, upset or confuse” the patients.
Leukaemia Research Fund - CML Booklet
http://leukaemialymphomaresearch.org.uk/information/download-our-patient-information-leaflets-and-booklets
Europe’s rare cancer community calls for a more radical approach Anna Wagstaff
'Europe’s rare cancer
community calls for
a more radical approach'
Anna Wagstaff
The genomic era offers enormous potential for patients with rare cancers, but progress is being held back by structures that separate research from care, regulatory practices that penalise small patient populations, and rules that restrict close working between researchers, companies, patients and regulators.
Anna Wagstaff
The genomic era offers enormous potential for patients with rare cancers, but progress is being held back by structures that separate research from care, regulatory practices that penalise small patient populations, and rules that restrict close working between researchers, companies, patients and regulators.
'Europe’s rare cancer
community calls for
a more radical approach'
Anna Wagstaff
The genomic era offers enormous potential for patients with rare cancers, but progress is being
held back by structures that separate research from care, regulatory practices that penalise
small patient populations, and rules that restrict close working between researchers,
companies, patients and regulators.
DH Guidlines on PCT Exceptional Cases Processes
Department of Health publishes guidance on exceptional cases processes
Wednesday, January 21, 2009
The Department of Health has published Defining Guiding Principles for Processes supporting Local Decision Making about Medicines.
Wednesday, January 21, 2009
The Department of Health has published Defining Guiding Principles for Processes supporting Local Decision Making about Medicines.
Department of Health publishes guidance on exceptional cases processes
Wednesday, January 21, 2009
The Department of Health has published Defining Guiding Principles for Processes supporting Local Decision Making about Medicines.
A Patients Right to Treatment- RCF booklet advising Consultants on how to appeal PCT negative funding decisions
Rarer Cancer Forum have produced a booklet to advice consultants on appealing negative funding decisions from PCT's...download booklet here
Rarer Cancer Forum have produced a booklet to advice consultants on appealing negative funding decisions from PCT's...download booklet here